ReviewRomanian journal of ophthalmology
Atypical Delayed-Onset Endophthalmitis Following Intravitreal Dexamethasone Implant Managed Without Implant Removal: A Rare Case Report and Literature Review.
Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report a case of atypical delayed-onset endophthalmitis following intravitreal dexamethasone (DEX) implantation, managed successfully without implant removal. Case presentation: A 72-year-old Asian woman with recurrent macular edema due to central retinal vein occlusion (CRVO) received an intravitreal DEX implant. Two weeks post-injection, she experienced blurred vision but no pain or redness. Best-corrected visual acuity (BCVA) had dropped to hand movements near the face (HMCF). Examination revealed 3+ anterior chamber cells and a 1.5 mm hypopyon, with significant vitreous haze obscuring retinal details. A diagnosis of acute endophthalmitis was made. Initial treatment with intravitreal vancomycin and ceftazidime was followed by pars plana vitrectomy (PPV) without implant removal. Microbiological tests were negative, and vision improved significantly, with BCVA returning to 6/12 after two weeks. Discussion: Endophthalmitis following DEX implantation is rare, and its management is not well-defined. While implant removal is often recommended, favorable outcomes can be achieved without it. The negative culture results and atypical presentation suggested a possible non-infectious etiology. Intraocular steroids may obscure typical signs of infection. Conclusion: Atypical delayed-onset endophthalmitis following DEX implantation can be successfully treated with prompt vitrectomy and intravitreal antibiotics without implant removal, underscoring the need for individualized management in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.